We provide you with 20 years of free, institutional-grade data for BCEL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BCEL. Explore the full financial landscape of BCEL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Atreca, Inc(PINK:BCEL) 
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery...
Website: http://www.atreca.com
Founded: 2010
IPO Price: $17 (Jun 20, 2019)
Full Time Employees: 128
CEO: John A. Orwin
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about BCEL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.